medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2007, Número 4

<< Anterior Siguiente >>

Ann Hepatol 2007; 6 (4)


Pathophysiology of ascites and dilutional hyponatremia: Contemporary use of aquaretic agents

García LJ, Martínez SJ, Estradas J, Torre A, Uribe M

Idioma: Ingles.
Referencias bibliográficas: 41
Paginas: 214-221
Archivo PDF: 185.07 Kb.


FRAGMENTO

Sin resumen


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Runyon BA. Care of patients with ascites. N Engl J Med 1994; 330: 337-342.

  2. Runyon BA. Management of adult patients with ascites due to cirrhosis. Hepatology 2004; 39: 841-854.

  3. Gines P, Beri T, Bernardi M, Bichet DG, Hamon G, Jimenez W, et al. Hyponatremia in cirrhosis: from pathogenesis to treatment. Hepatology 1998; 28: 851-861.

  4. Arroyo V. Pathophysiology, diagnosis and treatment of ascites in cirrhosis. Ann Hepatol 2002; 2: 72-79.

  5. Arroyo V, Colmenero J. Ascites and hepatorenal syndrome in cirrhosis: pathophysiology basis of therapy and current management. J Hepatol 2003; 38: S69-S89.

  6. Gines P, Cardenas A, Arroyo V, Rodes J. Management of cirrhosis and ascites. N Engl J Med 2004; 350: 1646-1654.

  7. Lieberman FL, Ito S, Reynolds TB. Effective plasma volume in cirrhosis with ascites. Evidence that a decreased value does not account for renal sodium retention, a sponteneous reduction in glomerular filtration rate (GFR), and a fall in GFR during drug-induced diuresis. J Clin Invest 1969; 48: 975-81.

  8. Gentilini P, Laffi G, La Villa G, Romanelli RG, Blendis LM. Ascites and hepatorenal syndrome in cirrhosis: two entities or the continuation of the same complication? J Hepatol 1999; 31: 1088-1097.

  9. Henriksen JH. Ascites and hepatorenal syndrome: recent advances in pathogenesis. J Hepatol 1995; 23(Supp 1): 25-30.

  10. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodes J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988; 8(5): 1151-7.

  11. Peña JC. Mecanismos renales y extrarenales en la retención de sodio y agua en la cirrosis con ascitis. Rev Invest Clin 1995; 47: 63-79.

  12. Rivera A, Peña JC, Barcena C, Rangel S, Dies F. Renal excretion of water, sodium and potassium in cirrhosis of the liver. Metabolism 1961; 10: 1-17.

  13. Henriksen JH. Ascites and hepatorenal syndrome: recent advances in pathogenesis. J Hepatol 1995; 23(Supp 1): 25-30.

  14. Aiza I, Perez GO, Schiff ER. Management of ascites in patients with chronic liver disease. Am J Gastroenterol 1994; 89: 1949-1955.

  15. Arroyo V, Gines P. Mechanism of sodium retention and ascites formation in cirrhosis. J Hepatol 1993; 17(suppl 2): S24-S28.

  16. Arroyo V, Claria J, Salo J. Antidiuretic hormona and the pathogenesis of water retention in cirrosis with ascites. Sem Liver Dis 1994; 14: 44-58.

  17. Boyer TD. Aquaretics in cirrhotics with hyponatremia. J Gastroenterol Hepatol 2004; 19: S191-S193.

  18. Moore KP, Wong F, Gines P, Bernardi M, Ochs A, Salerno F, et al. The management of ascites in cirrhosis: report on the consensus conference of the international ascites club. Hepatology 2003; 38: 258-266.

  19. Brater DC. Diuretic therapy. N Engl J Med 1998; 339: 387-395.

  20. Gines P, Arroyo V. Paracentesis in the management of cirrhotic ascites. J Hepatol 1993; 17(suppl 2): S14-S18.

  21. Arroyo V. Albumin in the treatment of liver disease – new features of a classical treatment. Aliment Pharmacol Ther 2002; 16 (suppl 5): 1-5.

  22. Torre Delgadillo A. Ascitis refractaria e hiponatremia dilucional: tratamiento actual y nuevos acuaréticos: Rev Gastroenterol Mex. 2005; 70(3): 299-311.

  23. Nejsum LN. The renal plumbing system: aquaporin water channels. Cell Mol Life Sci 2005; 62: 1692-1706.

  24. Preston GM, Carroll TP, Guggino WB, Agre P. Appearance of water channels in Xenopus oocytes expressing red cell CHIP28 protein. Science 1992; 256: 385-387.

  25. Nejsum LN. The renal plumbing system: aquaporin water channels. Cell Mol Life Sci 2005; 62: 1692-1706.

  26. Fernandez-Llama P, Turner R, Dibona G, Knepper MA. Renal expression of aquaporins in liver cirrhosis induced by chronic common bile duct ligation in rats. J Am Soc Nephrol 1999; 10: 1950-7.

  27. Fernandez-Llama P, Jimenez W, Bosch-Marce M, Arroyo V, Nielsen S, Knepper MA. Dysregulation of renal aquaporins and Na-Cl cotransporter in CCl4-induced cirrhosis. Kidney Int 2000; 58: 216-28.

  28. Tajika Y, Matsuzaki T, Suzuki T, Aoki T, Hagiwara H, Kuwahara M, et al. Aquaporin-2 is retrieved to the apical storage compartment via early endosomes and phosphatidylinositol 3-kinase-dependent pathway. Endocrinology 2004; 145: 4375-4383.

  29. Yamamoto T, Sasaki S, Fushimi K, Kawasaki K, Yaoita E, Oota K, et al. Localization and expression of a collecting duct water channel, aquaporin, in hydrated and dehydrated rats. J Exp Nephrol 1995; 3: 193-201.

  30. Gines P, Jimenez W. Aquaretic agents: a new potential treatment of dilutional hyponatremia in cirrhosis. J Hepatol 1996; 24: 506-512.

  31. Gadano A, Moreau R, Pessione F, Trombino C, Giuily N, Sinnassamy P, Valla D, Lebrec D. Aquaretic effects of niravoline, a k-opioid agonist, in patients with cirrhosis. Journal of Hepatology 2000; 32: 3842.

  32. Udelson JE, Smith WB, Hendrix GH, et al. Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 2001; 104: 2417-2423.

  33. Thibonnier M, Kilani A, Rahman M, et al. Effects of the nonpeptide V(1) vasopressin receptor antagonist SR49059 in hypertensive patients. Hypertension 1999: 34: 1293-1300.

  34. Ferguson JW, Therapondos G, Newby DE, Hayes PC. Therapeutic role of vasopressin receptor antagonism in patients with liver cirrhosis. Clin Sci (Lond) 2003; 105: 1-8.

  35. Chan PS, Coupet J, Park HC, Lai F, Hartupee D, Cervoni P, Dusza JP, et al. VPA-985, a nonpeptide orally active and selective vasopressin V2 receptor antagonist. Adv Exp Med Biol 1998; 449: 439-443.

  36. Wong F, Blei, AT, Blendis LM, Thuluvath PJ. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: A multicenter, randomized, placebo-controlled trial. Hepatology 2003; 37: 182-191.

  37. Inoue T, Ohnishi A, Matsuo A, Kawai B, Kunihiro N, Tada Y, Koizumi F, Chau T, Okada K, Yamamura Y, Tanaka T. Therapeutic and diagnostic potential of a vasopressin-2 antagonist for impaired water handling in cirrhosis. Clin Pharmacol Ther 1998; 63: 561-70.

  38. Guyader D, Patat A, Ellis-Grosse EJ, Orczyk GP. Pharmacodynamic effects of a nonpeptide antidiuretic hormone V2 antagonist in cirrhotic patients with ascites. Hepatology 2002; 36: 1197-1205.

  39. Patat A, Ellis-Grosse EJ, Orczyk GP, Gandon JM. Pharmacodynamic effects of a novel, non-peptide, V2 receptor antagonist, VPA-985, given with hydrochlorothiazide. Clin Pharmacol Ther 2000; 67: 110.

  40. Swan SK, Lambvrecht LJ, Orczyk GP, Ellis-Grosse EJ. Interaction between VPA-985, an ADH (V2) antagonist, and furosemide. J Am Soc Nephrol 1999; 10: 124A.

  41. Afdhal N, Andres Cardenas A, Gines P, Gross P, Verbalis J, Berl T, Schrier R, Bichet D, Wagoner L, Ouyang J. Randomized, placebo-controlled trial of tolvaptan, a novel v2-receptor antagonist, in hyponatremia: results of the salt 2 trial with emphasis on efficacy and safety in cirrhosis. Hepatology 2005; 42(S1): 756A.




2020     |     www.medigraphic.com